 <p class="lead" id="first">The <em>Journal of the National Cancer Institute</em> (JNCI) published a commentary today on the significant cancer disparities facing Asian Americans. The article is authored by seven researchers from across the country who participated in the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence "Conversations on Cancer" held on July 29, 2021. The virtual "conversation," the first by the FDA, focused on the unfair cancer burden impacting Asian Americans. The lead author of the commentary is Moon Chen, associate director for community outreach and engagement with the UC Davis Comprehensive Cancer Center.</p><p>In percentage terms, Asian Americans are the fastest-growing U.S. racial group for the past three censuses, yet data aggregation obscure distinctions within subgroups of the more than 24 million Asians living in the United States. The JNCI commentary illustrates the harmful impacts this is having on Asian American communities.</p><p>Chen said the neglect of Asian American cancer inequities stems from multiple factors. They include historical prejudices against Asian Americans and the myth of Asian Americans as the model healthy minority, compounded by language and cultural barriers as well as racism.</p><p>"Asian Americans are unique as the first U.S. population to experience cancer as the leading cause of death," said Chen. "Bigotry against Asian Americans, pervasive since the 19<sup>th</sup> century, but especially during the COVID-19 pandemic, is only exacerbating the cancer disparities that are costing Asian Americans their lives."</p><p><strong>High rates of certain cancer in Asian Americans</strong></p><p>The authors cite a disproportionate rate of certain cancers affecting Asian Americans including:</p><p>The authors note an "infinitesimal proportion" of the National Institutes of Health (NIH) budget funded Asian American research even though the population is experiencing the highest percentage increases of any U.S. racial population for the past three decades. Between 1992 and 2018, only 0.17% of the total budget of the NIH funded research on Asian Americans. A portfolio analysis of grants funded by the National Cancer Institute's Division of Cancer Control and Population Sciences showed a very limited number of studies focused on Asian Americans, with none at the time addressing the causes of cancer.</p><p>Asian Americans are also underrepresented in clinical trials. According to the commentary, only 1% of clinical trials emphasize racial and ethnic minority participation as a primary focus. Only 5 such trials focus on Asian Americans as compared with 83 for African Americans and 32 for Hispanics.</p><p>"Classifying Black Americans and Hispanic Americans as underrepresented minorities in clinical trials is helpful, but it is regrettable that our national policy excludes designating Asian Americans as underrepresented minorities, as documented by data in this commentary," said Chen. "There is a myth that Asian Americans don't get cancer, but that is far from the truth."</p><p><strong>What needs to happen to equalize cancer inequities</strong></p><p>To rectify inequities, the authors recommend a call to action:</p><p>"It is also important to focus on the impact of racism on cancer disparities and prioritize funding resources. Otherwise, we will not take the necessary steps forward for achieving health equity for Asian Americans," Chen added.</p><p>The other authors on this commentary include: Richard J. Lee, Ravi A. Madan, Van Ta Park, Susan M. Shinagawa, Tracy Sun, Scarlett L. Gomez.</p><p>The Oncology Center of Excellence at the FDA sponsored<em>Conversations on Cancer: Advancing Equity in Asian American and Pacific Islander Communities: Racism and Injustice</em>, which was the virtual panel discussion upon which the commentary is based. The work was supported by the National Institute on Aging (R24AG063718) and the National Cancer Institute (P30CA093373).</p>